Lipid Management Beyond Statins: Biologic Basis, New Clinical Evidence and Strategies- Enduring Activity

1.25 ACPE 1.2 ANCC Contact Hours 1 CDR 1.25 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Advanced Practice Registered Nurses, Nurse Practitioners, Pharmacists, Physician Assistants, Physicians, Registered Nurses, Registered Dietitians

Relevant Terms:

Peter Libby, MD, FACC

Peter Libby, MD, FACC
Cardiovascular Medicine
Brigham and Women's Hospital
Mallinckrodt Professor of Medicine
Harvard Medical School
Boston, MA

Peter Libby, MD, is a cardiovascular specialist at Brigham and Women's Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. He served as Chief of Cardiovascular Medicine at BWH from 1998 - 2014. His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has received numerous awards and recognitions for his research accomplishments, including the Gold Medal of the European Society of Cardiology (2011), the Basic Research Prize of the American Heart Association (2011), the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society (2013), and the Distinguished Achievement Award of the Heart Failure Association of the European Society of Cardiology (2014).
Dr. Libby's professional memberships include the Association of American Physicians, the American Society for Clinical Investigation, and elected honorary memberships in the British Atherosclerosis Society, the Japan Circulation Society, and the Japanese College of Cardiology. He has served as the President of the Association of University Cardiologists. He also has served in many roles as a volunteer for the American Heart Association, including chairman of several research committees and member of the executive committees of the Councils on Arteriosclerosis, Circulation, and Basic Science. He presided the American College of Cardiology's Research Allocations Peer Review Committee for two terms. He has frequently consulted for the National Heart, Lung, and Blood Institute, including a 5-year term on the Board of Scientific Councilors. He directed the DW Reynolds Cardiovascular Clinical Research Center and two cycles of Leducq Foundation Awards, and has received continuous funding from the NHLBI for several decades.
An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in medical journals including Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine, and Nature. He is an Editor of Braunwald's Heart Disease. Dr. Libby also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to many editions of Harrison's Principles of Internal Medicine. He has held numerous visiting professorships and delivered more than 80 major named or keynote lectures throughout the world.
Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women's Hospital). He also holds an honorary MA degree from Harvard University, and an honorary doctorate from the University of Lille, France

Harold E. Bays, MD, FTOS, FACC, FACE, FNLA

Harold E. Bays, MD, FTOS, FACC, FACE, FNLA
Medical Director / President
L-MARC Research Center
Louisville, KY

Dr. Harold Bays is Board Certified in Endocrinology and Internal Medicine, and has participated as an Investigator for over 400 Phase I - IV clinical trials regarding treatments for dyslipidemias, obesity, diabetes mellitus, hypertension, and other metabolic and hormonal disorders. As Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center, Dr. Bays has written, or served as a contributing author to ~ 200 published scientific manuscripts and book chapters, as well as over 100 scientific abstracts presented at major scientific meetings. He is a Fellow of the National Lipid Association (FNLA), Fellow of The Obesity Society (FTOS), and Fellow of the American Association of Clinical Endocrinologists (FACE). He has served as an advisor/consultant to numerous pharmaceutical companies with regard to drug development, protocol writing, statistical analyses, regulatory application, FDA Advisory panel presentations, and patent assistance. Dr. Bays originated the term "adiposopathy" ("sick fat"), which defines how and when the pathologic consequences of adipose tissue accumulation promotes metabolic disease, including dyslipidemia, diabetes mellitus, and hypertension.  Dr. Bays is a co-author of the American Society of Bariatric Physician Obesity Algorithm, and was Chairman of the National Lipid Association 2012 Adiposity and Dyslipidemia Consensus Conference and Chairman of the 2010 American Association of Clinical Endocrinologist Adipose Tissue Pathophysiology State of the Science Conference.

Michael Miller, MD, FACC, FAHA

Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine, Epidemiology & Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, MD

Dr. Miller is Professor of Medicine, Epidemiology and Public Health at the University of Maryland School of Medicine with ABIM certification in internal medicine and recertification in cardiovascular disease. He is also also a Diplomate of Clinical Lipidology. Dr. Miller has authored more than 250 original articles, book chapters and other publications that have appeared in BMJ, Circulation, JACC, JAMA, NEJM, PNAS and Science.  He is the co-author of "The Practice of Coronary Disease Prevention" (Lippincott, Williams & Wilkins, 1996), "The AMA Guide to Preventing and Treating Heart Disease" (Wiley, 2008) and "Heal Your Heart, The Positive Emotions Prescription to Prevent and Reverse Heart Disease" (Rodale, 2014).   Dr. Miller has contributed to the American College of Cardiology Self-Assessment Program (ACCSAP) for board certification and chaired the AHA Scientific Statement: Triglycerides and Cardiovascular Disease.   Currently, he is a Member of the AHA Nutrition Committee of the Lifestyle and Cardiometabolic Health Council and serves on Governor Martin O'Malley's Advisory Council on Heart Disease and Stroke Prevention.
1. Relate the key biologic pathways responsible for atherosclerotic disease and the mechanisms of therapies that inhibit its development.
2. Discuss the current clinical trial evidence of therapies that have been used as add-on therapy to statins to reduce CV events.
3. Incorporate risk assessment, guideline recommendations, and patient-centered approaches for add-on therapeutic decision-making for patients at high risk for CV events.
4. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families

Physicians, Nurse Practitioners, Physician Assistants, pharmacists, Registered Nurses, Advance Practice Registered Nurses, and Registered Dietitians with an interest in lipid management and CV disease risk reduction.
Statements of credit will be awarded based on the participant’s obtaining a 30% or greater total score on the activity post-test and completion and submission of the activity evaluation form.   If you have questions about this CME/CE activity, please contact the NLA at Please claim credit by August 17, 2016. For Pharmacists: Upon successfully completing the post-test with a score of 30% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks
This activity is supported by an educational grant from Amarin Pharma Inc.
CME credit provided by the National Lipid Association
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Lipid Association and Medtelligence. The National Lipid Association is accredited by the ACCME to provide continuing medical education for physicians.
The National Lipid Association designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1 Continuing Professional Education Units (CPEUs) for completion of this activity. CDR Accredited Provider #NL0002.
CE Credit provided by Postgraduate Institute for Medicine
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number 0809-9999-15-252-H01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education
This educational activity for 1.2 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designated for 0.8 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Name Relationship Company
Bays, Harold Consultant Amarin; Amgen; AstraZeneca; Bristol-Myers Squibb; Catabasis; Daiichi Sankyo, Inc.; Eisai; Eli Lilly; ISIS; Merck & Co., Inc.; Novartis; Novo Nordisk; Omthera; Pronovo; Sanofi; VIVUS; WPU
Contracted Research Amarin; Amgen; Ardea Inc.; Arisaph; California Raisin Board; Catabasis; Eisai; Elcelyx; Eli Lilly; Esperion; Gilead; Hoffman LaRoche; Home Access; Janssen; Johnson & Johnson; Merck & Co., Inc.; Nektar; Novartis; Novo Nordisk; Omthera; Orexigen Therapeutics; Pfizer; Pronovo; Sanofi; Takeda; TIMI; Trygg Pharmaceuticals; VIVUS; WPU
Speaker Amarin; Brisol-Myers Squibb; Daiichi Sakyo, Inc.; Eisai; Merck & Co., Inc.; Sanofi; VIVUS
Libby, Peter Advisory Board Athera biotechnologies; Interleukin Genetics
Consultant Amgen; AstraZeneca; Boehringer Ingleheim; Bristol-Myers Squibb; Eli Lilly and Company; Esperion Therapeutics; Genzyme; GlaxoSmithKline; ISIS Pharmaceuticals; KOWA Pharmaceuticals; Merck & Co., Inc.; Novartis; Pfizer; Sanofi-Regeneron; Takeda Pharmaceuticals
Contracted Research General Electric; GlaxoSmithKline; Novartis
Miller, Michael Consultant Amarin
Medtelligence N/A Medtelligence planner Ben Caref, PhD, has Nothing to Disclose.
NLA N/A Nothing to Disclose
PIM N/A PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Wild, Robert Consultant Atherotech
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above